China is serious about healthcare reform. New top-level guidelines will significantly reduce hospital revenue from medicine sales and promise more orders for medical equipment makers
China's policy on essential medicines will be overhauled as part of wide-ranging healthcare reforms. This may lead to the demise of many local pharmaceutical companies but opportunities in traditional Chinese medicine
China competition boost for Freshfields and ClearyFreshfields Bruckhaus Deringer is relocating one of its leading antitrust, competition and trade partners…
This is a transcript of a significant part of an interview conducted by China Law & Practice editor Phil Taylor with Yu Jianlong, vice-chairman and secretary-general of the China International Economic and Trade Arbitration Commission, on May 22 2009 in Hong Kong
For inbound investors, navigating the maze of available structures can be tricky. The development of the PRC Anti-monopoly Law has led to more scrutiny of acquisitions of Chinese companies, causing potential foreign investors to look at other ways of investing in the country; Danone's experience with Wahaha has in turn revealed potential pitfalls for joint ventures